

Jordi Ordonez-Llanos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9525348/publications.pdf>

Version: 2024-02-01

212
papers

9,453
citations

39113

52
h-index

56606

87
g-index

228
all docs

228
docs citations

228
times ranked

9872
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Assessment after ST-Segment Elevation Myocardial Infarction: Can Biomarkers Improve the Performance of Clinical Variables?. <i>Journal of Clinical Medicine</i> , 2022, 11, 1266.	1.0	1
2	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, . .	1.3	1
3	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2021, 67, 730-735.	1.5	28
4	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021, 27, 1456-1461.	0.7	1
5	Cardiac Biomarker Kinetics and Their Association With Magnetic Resonance Measures of Cardiomyocyte Integrity Following a Marathon Run: Implications for Postexercise Biomarker Testing. <i>Journal of the American Heart Association</i> , 2021, 10, e020039.	1.6	5
6	Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Na ^{-ve} and Switch Scenarios in HIV-Infected Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3456.	1.0	13
7	The Capacity of APOB-Depleted Plasma in Inducing ATP-Binding Cassette A1/G1-Mediated Macrophage Cholesterol Efflux ^{â€} But Not Gut Microbial-Derived Metabolites ^{â€} Is Independently Associated with Mortality in Patients with ST-Segment Elevation Myocardial Infarction. <i>Biomedicines</i> , 2021, 9, 1336.	1.4	3
8	A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure. <i>Frontiers in Physiology</i> , 2021, 12, 708890.	1.3	3
9	Cardiac dysfunction and remodeling regulated by anti-angiogenic environment in patients with preeclampsia: the ANGIOCOR prospective cohort study protocol. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 816.	0.9	1
10	Low-density lipoprotein aggregation is inhibited by apolipoprotein J-derived mimetic peptide D-[113 ^{â€} 122]apoJ. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158541.	1.2	7
11	Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. <i>PLoS ONE</i> , 2020, 15, e0237739.	1.1	10
12	Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113 ^{â€} 122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. <i>Biomolecules</i> , 2020, 10, 829.	1.8	18
13	Growth differentiation factor 15 as mortality predictor in heart failure patients with non ^{â€} reduced ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2223-2229.	1.4	19
14	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019, 65, 1221-1227.	1.5	21
15	Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes. <i>Clinical Biochemistry</i> , 2019, 73, 62-69.	0.8	7
16	Does Whole-Blood Neutrophil Gelatinase-Associated Lipocalin Stratify Acute Kidney Injury in Critically Ill Patients?. <i>Disease Markers</i> , 2019, 2019, 1-9.	0.6	6
17	High-sensitivity Cardiac Troponin for the Evaluation of Patients With Suspected ACS: A True or a False Friend?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 445-448.	0.4	2
18	P6437Growth differentiation factor-15 and stromal cell-derived factor-1 as long-term prognosis biomarkers in acute coronary syndrome. <i>European Heart Journal</i> , 2019, 40, .	1.0	0

#	ARTICLE	IF	CITATIONS
19	Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?. <i>Current Medicinal Chemistry</i> , 2019, 26, 1665-1679.	1.2	14
20	Fourth Universal Definition of Myocardial Infarction: Will it change how we practice emergency medicine?. <i>Emergencias</i> , 2019, 31, 55-57.	0.6	2
21	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2018, 64, 645-655.	1.5	327
22	Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 156.	2.7	26
23	High-Sensitivity Troponin T and Soluble Form of AXL as Long-Term Prognostic Biomarkers after Heart Transplantation. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	7
24	Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: Inhibitory effect of glycosaminoglycan sulodexide. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3559-3567.	1.8	19
25	Ultrasensitive quantification of cardiac troponin I by a Single Molecule Counting method: analytical validation and biological features. <i>Clinica Chimica Acta</i> , 2018, 486, 224-231.	0.5	38
26	Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy. <i>HIV Clinical Trials</i> , 2017, 18, 49-53.	2.0	0
27	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. <i>Clinical Chemistry</i> , 2017, 63, 542-551.	1.5	33
28	Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	64
29	High sensitivity cardiac troponin T in patients not having an acute coronary syndrome: results from the TRAPID-AMI study. <i>Biomarkers</i> , 2017, 22, 709-714.	0.9	9
30	Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. <i>Clinical Chemistry</i> , 2017, 63, 73-81.	1.5	277
31	Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. <i>Clinical Chemistry</i> , 2017, 63, 351-358.	1.5	58
32	Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients. <i>Atherosclerosis</i> , 2017, 265, 292-298.	0.4	14
33	Cardiac troponins: 25 years on the stage and still improving their clinical value. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 551-571.	2.7	7
34	P5287Time course of a set of biomarkers during compensation of an acute heart failure episode. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
35	Cell-cycle arrest biomarkers in urine to predict acute kidney injury in septic and non-septic critically ill patients. <i>Annals of Intensive Care</i> , 2017, 7, 92.	2.2	28
36	The Use of Very Low Concentrations of High-Sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. <i>Academic Emergency Medicine</i> , 2016, 23, 1004-1013.	0.8	64

#	ARTICLE	IF	CITATIONS
37	Prognostic Value of High-Sensitivity Troponin-T to Identify Patients at Risk of Left Ventricular Graft Dysfunction After Heart Transplantation. <i>Transplantation Proceedings</i> , 2016, 48, 3021-3023.	0.3	6
38	Inflammatory intracellular pathways activated by electronegative LDL in monocytes. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 963-969.	1.2	18
39	Documento de consenso y recomendaciones sobre el uso de los péptidos natriuréticos en la práctica clínica. <i>Revista Clinica Espanola</i> , 2016, 216, 313-322.	0.2	15
40	Electrophysiological Effects of Selective Atrial Coronary Artery Occlusion in Humans. <i>Circulation</i> , 2016, 133, 2235-2242.	1.6	40
41	Response by Álvarez-García et al to Letters Regarding Article, "Electrophysiological Effects of Selective Atrial Coronary Artery Occlusion in Humans". <i>Circulation</i> , 2016, 134, e401-e402.	1.6	0
42	Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 1015-1024.	1.2	6
43	Consensus document and recommendations on the use of natriuretic peptides in clinical practice. <i>Revista Clínica Española</i> , 2016, 216, 313-322.	0.3	4
44	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. <i>Annals of Emergency Medicine</i> , 2016, 68, 76-87.e4.	0.3	294
45	¿Quo vadis, troponina?. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 457-459.	0.6	1
46	The role of LDL-bound apoJ in the development of atherosclerosis. <i>Clinical Lipidology</i> , 2015, 10, 321-328.	0.4	5
47	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2015, 45, 899-905.	1.7	19
48	Urinary Neutrophil Gelatinase-Associated Lipocalin as Predictor of Short- or Long-Term Outcomes in Cardiac Surgery Patients. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1480-1488.	0.6	13
49	Cost-Effectiveness of Highly Sensitive Cardiac Troponin T to Rule Out Acute Rejection After Heart Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2395-2396.	0.3	2
50	Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 257-267.	1.2	12
51	Quo Vadis, Troponin?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 457-459.	0.4	0
52	Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. <i>Atherosclerosis</i> , 2015, 241, 463-470.	0.4	15
53	Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. <i>FASEB Journal</i> , 2015, 29, 1688-1700.	0.2	25
54	Electronegative LDL induces priming and inflammasome activation leading to IL-1 β release in human monocytes and macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 1442-1449.	1.2	35

#	ARTICLE	IF	CITATIONS
55	Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. <i>International Journal of Cardiology</i> , 2015, 201, 20-29.	0.8	33
56	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. <i>American Heart Journal</i> , 2015, 169, 6-16.e6.	1.2	89
57	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. <i>Clinical Biochemistry</i> , 2015, 48, 201-203.	0.8	224
58	Multiple biomarker strategies for risk stratification in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 120-125.	0.5	25
59	Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 70, 1130-8.	1.3	18
60	Inflammatory biomarkers in type 2 diabetic patients: effect of glycemic control and impact of ldl subfraction phenotype. <i>Cardiovascular Diabetology</i> , 2014, 13, 34.	2.7	47
61	Valor predictivo de la troponina T de alta sensibilidad para descartar el rechazo agudo tras un trasplante cardiaco. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 775-776.	0.6	6
62	Predictive Value of High-sensitive Troponin T to Rule Out Acute Rejection After Heart Transplantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 775-776.	0.4	6
63	Ceramide-enriched LDL induces cytokine release through TLR4 and CD14 in monocytes. Similarities with electronegative LDL. <i>Clínica E Investigación En Arteriosclerosis</i> , 2014, 26, 131-137.	0.4	17
64	Prognostic value of increased carbohydrate antigen in patients with heart failure. <i>World Journal of Cardiology</i> , 2014, 6, 205.	0.5	8
65	Eplerenone in systemic right ventricle: Double blind randomized clinical trial. The evedes study. <i>International Journal of Cardiology</i> , 2013, 168, 5167-5173.	0.8	60
66	Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2013, 12, 112.	2.7	47
67	Troponina cardiaca ultrasensible: de la teoría a la práctica clínica. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 687-691.	0.6	31
68	CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes. <i>Atherosclerosis</i> , 2013, 229, 356-362.	0.4	56
69	High-sensitivity Cardiac Troponin: From Theory to Clinical Practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 687-691.	0.4	23
70	Predicting future events in patients with stable cardiovascular disease. Will high-sensitivity cardiac troponins be up to the challenge?. <i>Clinical Biochemistry</i> , 2013, 46, 10-11.	0.8	2
71	Using High-sensitivity Troponin T: The Importance of the Proper Gold Standard. <i>American Journal of Medicine</i> , 2013, 126, 709-717.	0.6	54
72	The Induction of Cytokine Release in Monocytes by Electronegative Low-Density Lipoprotein (LDL) Is Related to Its Higher Ceramide Content than Native LDL. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2601-2616.	1.8	23

#	ARTICLE	IF	CITATIONS
73	Electronegative LDL: A Circulating Modified LDL with a Role in Inflammation. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	41
74	Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding. Current Opinion in Lipidology, 2012, 23, 479-486.	1.2	41
75	Commentary. Clinical Chemistry, 2012, 58, 44-44.	1.5	2
76	CardioPulse Articles. European Heart Journal, 2012, 33, 2883-2891.	1.0	3
77	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis, 2012, 225, 200-207.	0.4	30
78	Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. Gynecological Endocrinology, 2012, 28, 264-268.	0.7	7
79	Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. American Heart Journal, 2012, 163, 1002-1010.	1.2	72
80	Electronegative LDL: a useful biomarker of cardiovascular risk?. Clinical Lipidology, 2012, 7, 345-359.	0.4	15
81	Effect of Improving Glycemic Control in Patients With Type 2 Diabetes Mellitus on Low-Density Lipoprotein Size, Electronegative Low-Density Lipoprotein and Lipoprotein-Associated Phospholipase A2 Distribution. American Journal of Cardiology, 2012, 110, 67-71.	0.7	37
82	Increases in B-type natriuretic peptide for detecting weaning-induced heart failure: reply to Liu et al.. Intensive Care Medicine, 2012, 38, 174-174.	3.9	1
83	Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Research and Clinical Practice, 2011, 93, e25-e28.	1.1	15
84	Low-Density Lipoprotein Size and Lipoprotein-Associated Phospholipase A2 in HIV-Infected Patients Switching to Abacavir or Tenofovir. Antiviral Therapy, 2011, 16, 459-468.	0.6	22
85	Specific Characteristics of Sudden Death in a Mediterranean Spanish Population. American Journal of Cardiology, 2011, 107, 622-627.	0.7	59
86	Soluble ST2 Is a Marker for Acute Cardiac Allograft Rejection. Annals of Thoracic Surgery, 2011, 92, 2118-2124.	0.7	41
87	B-type natriuretic peptides for prediction and diagnosis of weaning failure from cardiac origin. Intensive Care Medicine, 2011, 37, 477-485.	3.9	85
88	Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults. AIDS Research and Human Retroviruses, 2011, 27, 1061-1065.	0.5	12
89	Immunochemical Analysis of the Electronegative LDL Subfraction Shows That Abnormal N-terminal Apolipoprotein B Conformation Is Involved in Increased Binding to Proteoglycans. Journal of Biological Chemistry, 2011, 286, 1125-1133.	1.6	27
90	Prevalence of Metabolic Syndrome Among Human Immunodeficiency Virus-Infected Subjects Is Widely Influenced by the Diagnostic Criteria. Metabolic Syndrome and Related Disorders, 2011, 9, 345-351.	0.5	13

#	ARTICLE	IF	CITATIONS
91	Atherogenesis and aggregated electronegative LDL. <i>Clinical Lipidology</i> , 2010, 5, 769-773.	0.4	0
92	Proteomic analysis of electronegative low-density lipoprotein. <i>Journal of Lipid Research</i> , 2010, 51, 3508-3515.	2.0	56
93	2D-NMR reveals different populations of exposed lysine residues in the apoB-100 protein of electronegative and electropositive fractions of LDL particles. <i>Journal of Lipid Research</i> , 2010, 51, 1560-1565.	2.0	20
94	Lipid Profile in Ambulatory Subjects Using 3 Point-of-Care Devices and Comparison With Reference Methods. <i>Point of Care</i> , 2010, 9, 102-107.	0.5	6
95	HDL and electronegative LDL exchange anti- and pro-inflammatory properties. <i>Journal of Lipid Research</i> , 2010, 51, 2947-2956.	2.0	24
96	Aggregated Electronegative Low Density Lipoprotein in Human Plasma Shows a High Tendency toward Phospholipolysis and Particle Fusion. <i>Journal of Biological Chemistry</i> , 2010, 285, 32425-32435.	1.6	46
97	New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. <i>Biomarkers</i> , 2010, 15, 307-314.	0.9	16
98	High Sensitivity Troponin in Chest Pain and Acute Coronary Syndromes. A Step Forward?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 763-769.	0.4	13
99	Soluble ST2 Monitoring Provides Additional Risk Stratification for Outpatients With Decompensated Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 1171-1178.	0.4	31
100	Electronegative LDL induces Fas and modifies gene expression in mononuclear cells. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 78-86.	0.9	10
101	High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. <i>Journal of Lipid Research</i> , 2009, 50, 446-455.	2.0	31
102	Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2174-2179.	1.2	205
103	Potential of mid-infrared spectroscopy to aid the triage of patients with acute chest pain. <i>Analyst, The</i> , 2009, 134, 1092.	1.7	39
104	The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. <i>European Heart Journal</i> , 2009, 30, 1088-1096.	1.0	194
105	Lipid Profile in Ambulatory Patients Using 3 Point-of-Care Devices and Comparison With Reference Methods. <i>Point of Care</i> , 2009, 8, 110-116.	0.5	5
106	Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins. <i>International Journal of Biomedical Science</i> , 2009, 5, 402-10.	0.5	8
107	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. <i>Clinical Biochemistry</i> , 2008, 41, 222-226.	0.8	24
108	The Effects of Liposuction Removal of Subcutaneous Abdominal Fat on Lipid Metabolism are Independent of Insulin Sensitivity in Normal-Overweight Individuals. <i>Obesity Surgery</i> , 2008, 18, 408-414.	1.1	56

#	ARTICLE	IF	CITATIONS
109	Multicentric evaluation of the homogeneous LDL-cholesterol Plus assay: Comparison with beta-quantification and Friedewald formula. <i>Clinical Biochemistry</i> , 2008, 41, 1402-1409.	0.8	17
110	Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels. <i>European Journal of Human Genetics</i> , 2008, 16, 1372-1379.	1.4	24
111	Amino-Terminal Pro-B-Type Natriuretic Peptide: Analytic Considerations. <i>American Journal of Cardiology</i> , 2008, 101, S9-S15.	0.7	66
112	HDL COUNTERACTS INFLAMMATORY PROPERTIES OF ELECTRONEGATIVE LDL (LDL(-)). <i>Atherosclerosis Supplements</i> , 2008, 9, 50.	1.2	0
113	Combination of clinical risk profile, early exercise testing and circulating biomarkers for evaluation of patients with acute chest pain without ST-segment deviation or troponin elevation. <i>Heart</i> , 2008, 94, 311-315.	1.2	22
114	Novel Phospholipolytic Activities Associated with Electronegative Low-Density Lipoprotein Are Involved in Increased Self-Aggregation. <i>Biochemistry</i> , 2008, 47, 8186-8194.	1.2	40
115	Natriuretic peptide testing in emergency settings. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1543-9.	1.4	4
116	Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. <i>European Heart Journal</i> , 2008, 29, 1011-1018.	1.0	71
117	Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. <i>Clinical Chemistry</i> , 2008, 54, 619-621.	1.5	124
118	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 547-551.	1.5	188
119	Left atrial enlargement and NT-proBNP as predictors of sudden cardiac death in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 802-807.	2.9	42
120	Pro-inflammatory action of LDL(β^2) on mononuclear cells is counteracted by increased IL10 production. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2007, 1771, 613-622.	1.2	34
121	Atherogenic and inflammatory profile of human arterial endothelial cells (HUAEC) in response to LDL subfractions. <i>Clinica Chimica Acta</i> , 2007, 376, 233-236.	0.5	20
122	Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. <i>International Journal of Cardiology</i> , 2007, 120, 338-343.	0.8	36
123	Inducción de citocinas por efecto de la LDL electronegativa en monocitos y linfocitos. <i>Clinica E Investigaci3n En Arteriosclerosis</i> , 2007, 19, 13-21.	0.4	0
124	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure. <i>Circulation</i> , 2007, 116, e95-8.	1.6	79
125	Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 26-34.	1.7	23
126	Effect of Body Mass Index on Diagnostic and Prognostic Usefulness of Amino-Terminal Pro-Brain Natriuretic Peptide in Patients With Acute Dyspnea. <i>Archives of Internal Medicine</i> , 2007, 167, 400.	4.3	125

#	ARTICLE	IF	CITATIONS
127	NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. <i>European Heart Journal</i> , 2006, 27, 330-337.	1.0	978
128	Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1437-1442.	1.5	13
129	Risk stratification of chest pain patients by point-of-care cardiac troponin T and myoglobin measured in the emergency department. <i>Clinica Chimica Acta</i> , 2006, 365, 93-97.	0.5	16
130	Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 1014-1021.	1.2	48
131	Antiatherogenic role of high-density lipoproteins: insights from genetically engineered-mice. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1328.	3.0	18
132	Apolipoprotein A5 S19W May Play a Role in Dysbetalipoproteinemia in Patients with the Apo E2/E2 Genotype. <i>Clinical Chemistry</i> , 2006, 52, 1974-1975.	1.5	14
133	The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. <i>Diabetologia</i> , 2005, 48, 2162-2169.	2.9	47
134	A cause of falsely low HDL concentrations in HIV-infected patients: increased polyclonal serum immunoglobulin. <i>Clinical Biochemistry</i> , 2005, 38, 46-49.	0.8	5
135	Metabolic Syndrome Among HIV-Infected Patients: Prevalence, characteristics, and related factors. <i>Diabetes Care</i> , 2005, 28, 132-137.	4.3	223
136	Triglyceride-to-HDL Cholesterol Ratio in the Dyslipidemic Classification of Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1798-1800.	4.3	9
137	A Genomewide Exploration Suggests a New Candidate Gene at Chromosome 11q23 as the Major Determinant of Plasma Homocysteine Levels: Results from the GAIT Project. <i>American Journal of Human Genetics</i> , 2005, 76, 925-933.	2.6	90
138	Metabolic syndrome at follow-up in women with and without gestational diabetes mellitus in index pregnancy. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1115-1121.	1.5	60
139	Role of hs-CRP measurements in the current cardiovascular risk assessment. <i>Clinica Chimica Acta</i> , 2005, 355, 215-218.	0.5	8
140	Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia: a longitudinal study. <i>Diabetes Research and Clinical Practice</i> , 2005, 68, 81-83.	1.1	7
141	Anthropometrical measures are easily obtainable sensitive and specific predictors of insulin resistance in healthy individuals. <i>Prevention and Control: the Official Journal of the World Heart Federation</i> , 2005, 1, 175-181.	0.3	8
142	NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. <i>Journal of Cardiac Failure</i> , 2005, 11, S3-S8.	0.7	80
143	Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties. <i>Circulation Research</i> , 2004, 95, 789-797.	2.0	118
144	Ischemia-Modified Albumin during Skeletal Muscle Ischemia. <i>Clinical Chemistry</i> , 2004, 50, 1063-1065.	1.5	95

#	ARTICLE	IF	CITATIONS
145	N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2004, 6, 301-308.	2.9	169
146	Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. <i>American Journal of Cardiology</i> , 2004, 93, 414-420.	0.7	43
147	N-terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. <i>American Journal of Cardiology</i> , 2004, 94, 669-670.	0.7	17
148	Impaired Binding Affinity of Electronegative Low-Density Lipoprotein (LDL) to the LDL Receptor Is Related to Nonesterified Fatty Acids and Lysophosphatidylcholine Content. <i>Biochemistry</i> , 2004, 43, 15863-15872.	1.2	49
149	LDL electronegativa: una LDL modificada presente en la circulaci3n con caracter4sticas aterog4nicas. <i>Cl4nica E Investigaci3n En Arteriosclerosis</i> , 2004, 16, 154-159.	0.4	1
150	Emerging cardiovascular risk factors in subclinical hypothyroidism: Lack of change after restoration of euthyroidism. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1512-1515.	1.5	47
151	Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1516.	1.5	1
152	Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration. <i>Atherosclerosis</i> , 2004, 174, 275-285.	0.4	9
153	Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. <i>Atherosclerosis</i> , 2004, 177, 299-305.	0.4	28
154	Electronegative low-density lipoprotein. <i>Current Opinion in Lipidology</i> , 2004, 15, 329-335.	1.2	109
155	The effect of VLDL particles on the accuracy of a direct LDL-cholesterol method in type 2 diabetic patients. <i>Clinical Biochemistry</i> , 2003, 36, 177-183.	0.8	12
156	Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. <i>Atherosclerosis</i> , 2003, 166, 261-270.	0.4	96
157	Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women. <i>Atherosclerosis</i> , 2003, 167, 327-334.	0.4	227
158	Postprandial lipidemia is normal in non-obese type 2 diabetic patients with relatively preserved insulin secretion. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1038-1042.	1.5	7
159	Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1576-1578.	1.5	14
160	Non-HDL Cholesterol and Apolipoprotein B in the Dyslipidemic Classification of Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2003, 26, 2048-2051.	4.3	54
161	Platelet-Activating Factor Acetylhydrolase Is Mainly Associated With Electronegative Low-Density Lipoprotein Subfraction. <i>Circulation</i> , 2003, 108, 92-96.	1.6	101
162	Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3212-3217.	1.8	36

#	ARTICLE	IF	CITATIONS
163	Mechanisms of HDL deficiency in mice overexpressing human apoA-II. <i>Journal of Lipid Research</i> , 2002, 43, 1734-1742.	2.0	25
164	Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. <i>Atherosclerosis</i> , 2002, 160, 223-232.	0.4	77
165	Apolipoproteins and prediction of fatal myocardial infarction. <i>Lancet, The</i> , 2002, 359, 1863.	6.3	3
166	Diabetes mellitus and cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2002, 13, 15-30.	1.0	12
167	LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. <i>Acta Diabetologica</i> , 2002, 39, 215-220.	1.2	45
168	Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. <i>Journal of Lipid Research</i> , 2002, 43, 699-705.	2.0	81
169	ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia. <i>Journal of Lipid Research</i> , 2002, 43, 115-123.	2.0	24
170	Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. <i>Journal of Lipid Research</i> , 2002, 43, 699-705.	2.0	66
171	Apo(B)-dependent dyslipidemic phenotypes in type 1 diabetic patients. <i>European Journal of Internal Medicine</i> , 2001, 12, 496-502.	1.0	1
172	LOW-DENSITY LIPOPROTEIN PARTICLE SIZE, TRIGLYCERIDE-RICH LIPOPROTEINS, AND GLUCOSE TOLERANCE IN NON-DIABETIC MEN WITH ESSENTIAL HYPERTENSION. <i>Clinical and Experimental Hypertension</i> , 2001, 23, 489-500.	0.5	17
173	Effect of Glycemic Optimization on Electronegative Low-Density Lipoprotein in Diabetes: Relation to Nonenzymatic Glycosylation and Oxidative Modification1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3243-3249.	1.8	60
174	ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. <i>Journal of Lipid Research</i> , 2001, 42, 241-248.	2.0	42
175	Effect of Glycemic Optimization on Electronegative Low-Density Lipoprotein in Diabetes: Relation to Nonenzymatic Glycosylation and Oxidative Modification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3243-3249.	1.8	49
176	Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C Plus assay?. <i>Clinical Chemistry</i> , 2001, 47, 124-6.	1.5	10
177	ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. <i>Journal of Lipid Research</i> , 2001, 42, 241-8.	2.0	39
178	Usual delay in sample processing can modify gestational diabetes screening. <i>Diabetes Care</i> , 2000, 23, 429-429.	4.3	8
179	Role of neuropeptides in heart failure: preliminary information or knowledge?. <i>European Journal of Clinical Investigation</i> , 2000, 30, 561-562.	1.7	2
180	Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome. <i>Journal of Molecular Medicine</i> , 2000, 78, 147-154.	1.7	9

#	ARTICLE	IF	CITATIONS
181	Electronegative LDL From Normolipemic Subjects Induces IL-8 and Monocyte Chemotactic Protein Secretion by Human Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2281-2287.	1.1	104
182	Comparison of the Abbott IMx [®] and a High-Performance Liquid Chromatography Method for Measuring Total Plasma Homocysteine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 327-9.	1.4	25
183	Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1488, 233-244.	1.2	31
184	Effect of physical exercise on lipoprotein(a) and low-density lipoprotein modifications in Type 1 and Type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 640-647.	1.5	56
185	Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2000, 41, 1328-1338.	2.0	59
186	Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. <i>Journal of Lipid Research</i> , 2000, 41, 1328-38.	2.0	48
187	Apolipoprotein(B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients. <i>Diabetes Care</i> , 1999, 22, 812-817.	4.3	64
188	Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 1999, 84, 655-659.	0.7	76
189	Effects of a short-acting insulin analog (insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 371-376.	1.5	21
190	Plasma Lipoprotein(a) Levels Are Not Influenced by Glycemic Control in Type 1 Diabetes. <i>Diabetes Care</i> , 1998, 21, 1517-1520.	4.3	9
191	Ascorbic acid inhibits the increase in low-density lipoprotein (LDL) susceptibility to oxidation and the proportion of electronegative LDL induced by intense aerobic exercise. <i>Coronary Artery Disease</i> , 1998, 9, 249-256.	0.3	29
192	Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. <i>Journal of Lipid Research</i> , 1998, 39, 457-462.	2.0	61
193	Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. <i>Journal of Lipid Research</i> , 1998, 39, 457-62.	2.0	52
194	Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients. <i>Diabetes Care</i> , 1997, 20, 1459-1461.	4.3	15
195	Optimization of Glycemic Control by Insulin Therapy Decreases the Proportion of Small Dense LDL Particles in Diabetic Patients. <i>Diabetes</i> , 1997, 46, 1207-1213.	0.3	70
196	LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects. <i>Atherosclerosis</i> , 1997, 132, 207-213.	0.4	67
197	Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. <i>Diabetes</i> , 1997, 46, 1207-1213.	0.3	37
198	Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia. <i>Clinical Chemistry</i> , 1997, 43, 808-15.	1.5	18

#	ARTICLE	IF	CITATIONS
199	Lipoprotein(a) concentrations and non-insulin-dependent diabetes mellitus: relationship to glycaemic control and diabetic complications. <i>Diabetes Research and Clinical Practice</i> , 1996, 33, 105-110.	1.1	10
200	Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. <i>Journal of Molecular Medicine</i> , 1996, 74, 771-776.	1.7	29
201	Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. <i>Nephrology Dialysis Transplantation</i> , 1995, 10, 537-540.	0.4	26
202	Increase of LDL susceptibility to oxidation occurring after intense, long duration aerobic exercise. <i>Atherosclerosis</i> , 1995, 118, 297-305.	0.4	73
203	Diagnostic specificity of creatine kinase-MB isoenzyme in physically active subjects.. <i>Circulation</i> , 1994, 89, 1447-1448.	1.6	3
204	Marathon runners presented lower serum cholesteryl ester transfer activity than sedentary subjects. <i>Atherosclerosis</i> , 1993, 101, 43-49.	0.4	29
205	LDL binding sites on platelets differ from the "classical" receptor of nucleated cells.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1992, 12, 1353-1362.	3.8	43
206	Ratio of Creatine Kinase 2 Mass Concentration to Total Creatine Kinase Activity not Altered by Heavy Physical Exercise. <i>Clinical Chemistry</i> , 1992, 38, 2224-2227.	1.5	12
207	Creatine Kinase MB Isoforms in Patients with Skeletal Muscle Injury: Ramifications for Early Detection of Acute Myocardial Infarction. <i>Clinical Chemistry</i> , 1992, 38, 2396-2400.	1.5	52
208	Ratio of creatine kinase 2 mass concentration to total creatine kinase activity not altered by heavy physical exercise. <i>Clinical Chemistry</i> , 1992, 38, 2224-7.	1.5	3
209	Transient alterations in cardiac performance after a six-hour race. <i>American Journal of Cardiology</i> , 1990, 65, 1471-1474.	0.7	31
210	Antibody binding serum T3 in a patient with hepatocarcinoma. <i>Journal of Endocrinological Investigation</i> , 1984, 7, 123-128.	1.8	10
211	Thyroid hemiagenesis in two sisters. <i>Journal of Endocrinological Investigation</i> , 1984, 7, 393-394.	1.8	42
212	Circulant anti-triiodothyronine antibodies in a patient with graves' disease: effects on measurement of T3 with different ria procedures. <i>Clinica Chimica Acta</i> , 1980, 106, 173-181.	0.5	21